IL-1β
Pro-inflammatory cytokine
- Expression
- elevated
- Evidence level
- established
- Targeted by
- Anakinra, Canakinumab
Role in pathogenesis
Central disease mediator: drives fever, rash, joint symptoms, CRP/SAA elevation, and systemic inflammation. CAPS is the prototypical IL-1β-driven disease. Dramatic response to IL-1 blockade proves its pathogenic role.
Targeting drugs (2)
| Drug | Mechanism | Response | Line |
|---|---|---|---|
| Anakinra | IL-1 receptor antagonist | Sustained efficacy up to 5 years | 1st |
| Canakinumab | Anti-IL-1β monoclonal antibody | 78-97% complete response | 1st |
Sources (3)
G1Goldbach-Mansky R et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition · N Engl J MedPubMed ↗
H1Lachmann HJ et al. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome · N Engl J MedPubMed ↗
B1Putnam CD et al. (2024) The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity · Immunol RevPubMed ↗